BioNTech, the German biotech group behind the first approved Covid-19 vaccine, warned there was “no data” to support moves to delay the second dose of the jab with the aim of reaching as many people as possible with limited supplies.
研发了首款获批新型冠状病毒肺炎（COVID-19，即2019冠状病毒病）疫苗的德国生物科技企业BioNTech警告称，为了在疫苗供应有限的情况下尽可能覆盖更多人而延迟第二针接种的举动，是“没有数据”支持的。
您已阅读5%（336字），剩余95%（6307字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。